It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage oncology company focused on developing therapies with its SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform
- Lead asset ADP-A2M4= in P2b/3 study (SPEARHEAD-1) as monotherapy and in head and neck cancer in combo with Merck’s Keytruda (SPEARHEAD-2)
- ADP-A2M4 has regenerative medicine advanced therapy (RMAT) and Orphan Drug (OD) designations
- Has a collaboration and license agreement with big pharma company GSK